<p>欢迎来到 <em>Pharmaceutical Executive Daily</em>，这是您快速了解制药和生命科学行业最新动态的简报。</p>
<p>在今天的 <em>Pharmaceutical Executive Daily</em> 中，FDA 延长了对 Leqembi 皮下制剂的优先审查，行业分析师研究即将到来的 GLP-1 专利到期如何重塑药物输送设备市场，专家讨论推动放射药物重新增长的关键因素。</p>
<p>FDA 对 Leqembi 一周一次的皮下制剂的补充生物制品许可申请进行了优先审查，将该机构的行动日期推迟了三个月。该申请旨在为早期阿尔茨海默病患者提供更方便的给药选择，随着对能够减少与输注治疗相关负担的疗法需求的增长而提出。该机构要求提供与提交相关的额外信息，但不需要新的临床研究。</p>
<p>随着 GLP-1 疗法继续重塑代谢疾病市场，越来越多的关注转向关键专利及其对仿制药和药物输送技术的影响。行业观察人士指出，这一过渡可能会显著改变采购策略，并加剧围绕注射设备、自注射器和与肥胖和糖尿病治疗相关的输送平台的竞争。预计未来几年将有多家公司追求后续或仿制版的畅销 GLP-1 药物，设备差异化可能成为关键的竞争因素。</p>
<p>最后，随着靶向技术、同位素生产和临床验证的进步，放射药物正在经历增长，继续扩大该领域在肿瘤学中的潜力。行业专家指出，投资活动的增加和战略合作伙伴关系的增多是主要制药公司寻求接触能够提供高度靶向癌症治疗的模式的重要因素。</p>
<p>感谢您收听 <em>Pharmaceutical Executive Daily</em>。欲获取更多更新和深入分析，请访问 PharmExec.com。</p>

礼来

诺和诺德公司

标普健康医疗设备 ETF - SPDR

<p>美国食品药品监督管理局（FDA）已将针对早期阿尔茨海默病患者的 Leqembi 皮下制剂的优先审查延长了三个月。分析师们还关注即将到来的 GLP-1 专利到期，这可能会影响药物输送设备市场，加剧注射设备的竞争。此外，放射药物的进展正在推动肿瘤学的增长，主要制药公司之间的投资和战略合作也在增加</p>

<p>Welcome to <em>Pharmaceutical Executive Daily</em>, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.</p>
<div class="lb-trans"><p>欢迎来到 <em>Pharmaceutical Executive Daily</em>，这是您快速了解制药和生命科学行业最新动态的简报。</p>
</div><p>In today’s <em>Pharmaceutical Executive Daily</em>, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape the drug delivery device market, and experts discuss the key forces driving renewed growth in radiopharmaceuticals.</p>
<div class="lb-trans"><p>在今天的 <em>Pharmaceutical Executive Daily</em> 中，FDA 延长了对 Leqembi 皮下制剂的优先审查，行业分析师研究即将到来的 GLP-1 专利到期如何重塑药物输送设备市场，专家讨论推动放射药物重新增长的关键因素。</p>
</div><p>FDA has priority review of the supplemental biologics license application for a once-weekly subcutaneous formulation of Leqembi, pushing the agency’s action date back by three months. The application seeks approval for a more convenient administration option for patients with early Alzheimer disease and comes as demand grows for therapies that can reduce the burden associated with infusion-based treatment. The agency requested additional information related to the submission, though no new clinical studies were required.</p>
<div class="lb-trans"><p>FDA 对 Leqembi 一周一次的皮下制剂的补充生物制品许可申请进行了优先审查，将该机构的行动日期推迟了三个月。该申请旨在为早期阿尔茨海默病患者提供更方便的给药选择，随着对能够减少与输注治疗相关负担的疗法需求的增长而提出。该机构要求提供与提交相关的额外信息，但不需要新的临床研究。</p>
</div><p>As GLP-1 therapies continue reshaping the metabolic disease market, attention is increasingly turning toward the of key patents and what that could mean for both generics and drug delivery technologies. Industry observers note that the transition could dramatically alter procurement strategies and intensify competition around injection devices, autoinjectors, and delivery platforms tied to obesity and diabetes treatments. With multiple companies expected to pursue follow-on or generic versions of blockbuster GLP-1 drugs in the coming years, device differentiation may become a critical competitive factor.</p>
<div class="lb-trans"><p>随着 GLP-1 疗法继续重塑代谢疾病市场，越来越多的关注转向关键专利及其对仿制药和药物输送技术的影响。行业观察人士指出，这一过渡可能会显著改变采购策略，并加剧围绕注射设备、自注射器和与肥胖和糖尿病治疗相关的输送平台的竞争。预计未来几年将有多家公司追求后续或仿制版的畅销 GLP-1 药物，设备差异化可能成为关键的竞争因素。</p>
</div><p>Finally, radiopharmaceuticals are experiencing as advances in targeting technology, isotope production, and clinical validation continue to expand the field’s potential in oncology. Industry experts point to growing investment activity and an increasing number of strategic partnerships as major pharmaceutical companies seek exposure to a modality capable of delivering highly targeted cancer treatment.</p>
<div class="lb-trans"><p>最后，随着靶向技术、同位素生产和临床验证的进步，放射药物正在经历增长，继续扩大该领域在肿瘤学中的潜力。行业专家指出，投资活动的增加和战略合作伙伴关系的增多是主要制药公司寻求接触能够提供高度靶向癌症治疗的模式的重要因素。</p>
</div><p>Thanks for listening to <em>Pharmaceutical Executive Daily</em>. For more updates and in-depth analysis, visit PharmExec.com.</p>
<div class="lb-trans"><p>感谢您收听 <em>Pharmaceutical Executive Daily</em>。欲获取更多更新和深入分析，请访问 PharmExec.com。</p>
</div>

<![CDATA[Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA]]>

Pharmexec

2 倍做多 LLY ETF - Direxion

2 倍做多 NVO ETF - Defiance

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

2 倍做多 LLY ETF - Defiance

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

美国医药设备 ETF - iShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

制药高管日报：FDA 延长了对 Leqembi 补充生物制品许可申请的审查时间